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atherosclerotic disease remain the  leading 
cause of morbidity and mortality in patients 
with T2D.1‑5
Red blood cell distribution width (RDW) is 
a simple measure of red blood cell (RBC) size 
heterogeneity (ie, anisocytosis), which is calcu-
lated by dividing the standard deviation (SD) of 
INTRODUCTION Type 2 diabetes (T2D) rep-
resents a serious threat to global public health, 
currently affecting an estimated 451 million 
people worldwide.1 ‑5 Atherosclerotic cardio-
vascular diseases (ASCVDs), including coro-
nary artery disease (CAD), cerebrovascular 
disease, peripheral artery disease, and aortic 
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BACKGROUND Previous studies have shown that red blood cell distribution width (RDW) is an independent 
predictor of poor prognosis in type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). 
The mechanisms underlying increased anisocytosis in patients with T2D and confirmed ASCVD remain 
poorly understood.
AIMS We sought to evaluate the relationship among the leptin-to-adiponectin ratio, systemic low -grade 
inflammation, and RDW in optimally treated patients with T2D and established ASCVD.
METHODS A total of 68 patients, aged 47 to 85 years (mean [SD], 65.3 [6.8] years) and including 21 women 
(30.9%), were enrolled and grouped according to median RDW into those with RDW <13.5% (n = 33) and 
those with RDW ≥13.5% (n = 35).
RESULTS Patients with RDW ≥13.5% had a significantly higher median (interquartile range [IQR]) serum 
leptin-to-adiponectin ratio (1.7 [0.49–2.3] ng/µg vs 0.66 [0.31–1.25] ng/µg; P = 0.04) and median (IQR) 
tumor necrosis factor α levels (1.58 [1.42–1.97] pg/ml vs 1.39 [1.18–1.57] pg/ml; P = 0.02). There were no 
significant differences in the concentrations of other inflammatory markers. The leptin-to-adiponectin 
ratio (r = 0.25; P = 0.04) and levels of tumor necrosis factor α (r = 0.32; P = 0.01) and soluble intercellular 
adhesion molecule 1 (r = 0.31; P = 0.01) were positively correlated with RDW, which was confirmed by 
univariate linear regression analysis. A multivariable regression model, which included demographic, 
clinical, and laboratory data, showed that white blood cell count (β = 0.25; 95% CI, 0.05–0.45; P = 0.01), 
soluble intercellular adhesion molecule 1 levels (β = 0.21; 95% CI, 0.02–0.41; P = 0.03), and mean corpuscular 
hemoglobin concentration (MCHC), (β = –0.48; 95% CI, 0.67 to –0.28; P <0.001) were independent predictors 
of RDW in our patients.
CONCLUSIONS In well -controlled patients with T2D and ASCVD, the RDW values are associated with 
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and established ASCVD were enrolled. The me-
dian (interquartile range) duration of diabe-
tes was 10 (6–15) years. Diabetic patients were 
grouped according to the median value of RDW 
into those with RDW <13.5% (n = 33) and those 
with RDW ≥13.5% (n = 35). Obesity was defined 
as body mass index higher or equal to 30 kg/m2. 
The assessment of body composition was per-
formed using bioelectrical impedance analysis.
The  study was conducted according to 
the guidelines laid down in the Declaration of 
Helsinki and all procedures involving human 
subjects were approved by the local ethics com-
mittee (KBET/190/B/2012). Written informed 
consent was obtained from all participants.
Sample collection and laboratory tests 
Blood samples (25 ml) were obtained from 
the antecubital vein between 8 AM and 10 AM 
after an overnight fast. They were processed 30 
to 60 minutes after blood collection. Then, se-
rum samples were stored at –70 °C until further 
analysis. Complete blood count, including RBCs, 
hemoglobin, hematocrit, MCV, mean corpuscu-
lar hemoglobin (MCH), mean corpuscular he-
moglobin concentration (MCHC), RDW, white 
blood cells (WBCs), neutrophils, lymphocytes, 
platelet count, and mean platelet volume, was 
assayed using the hematological analyzer Sys-
mex XT2000i (Sysmex Corporation, Kobe, Ja-
pan). Anemia was defined according to the WHO 
guidelines as blood hemoglobin concentration 
below 12 g/dl in women and below 13 g/dl in 
men.21
Routine blood tests, including lipid profile (to-
tal cholesterol, low -density lipoprotein choles-
terol [LDL -C], high -density lipoprotein choles-
terol [HDL -C], and triglycerides [TG]) and serum 
creatinine concentration, were performed using 
automated laboratory techniques. An estimat-
ed glomerular filtration rate (eGFR) was calcu-
lated by the abbreviated Modification of Diet in 
Renal Disease (MDRD) Study equation. The lev-
els of HbA1c were determined using a direct tur-
bidimetric inhibition immunoassay.
Latex -enhanced nephelometry (Dade Behring, 
Marburg, Germany) was used for the measure-
ment of fibrinogen and high -sensitivity C -re-
active protein (hs -CRP) levels. The concentra-
tions of IL-6, TNF -α, soluble intercellular ad-
hesion molecule 1 (sICAM-1), soluble vascular 
adhesion molecule 1 (sVCAM-1), and myeloper-
oxidase were measured by an enzyme -linked 
immunosorbent assay (R&D Systems, Minne-
apolis, Minnesota, United States).
Serum leptin and adiponectin levels were 
determined using radioimmunoassay kits (DI-
Asource, Louvain-la-Neuve, Belgium). The ac-
tivity of lipoprotein -associated phospholipase 
A2 (Lp -PLA2) was measured with a colorimet-
ric activity method assay (diaDexus, Inc., San 
Francisco, California, United States), in which 
RBC volumes by the mean corpuscular volume 
(MCV).6‑12 There is increasing evidence that an-
isocytosis measured by RDW values is increased 
in patients with T2D and ASCVD.6‑12 Further-
more, recent studies have shown that RDW is 
an independent predictor of poor prognosis in 
subjects with T2D and ASCVD.12‑14 The mecha-
nisms underlying increased anisocytosis in pa-
tients with T2D and confirmed ASCVD remain 
poorly understood. The results of experimental 
and clinical studies indicate a possible associa-
tion of adipose tissue and adipokines, includ-
ing leptin, adiponectin, interleukin 6 (IL-6), and 
tumor necrosis factor α (TNF -α), with hemato-
poiesis.14‑20 There are preliminary data suggest-
ing that proinflammatory leptin, whose recep-
tors have been found on the surface of hemato-
poietic cells, and anti -inflammatory adiponec-
tin may be particularly important for hemato-
poiesis and possibly affect anisocytosis in both 
diabetic and nondiabetic patients.15‑18
The aim of this study was to evaluate the rela-
tionship among the leptin-to-adiponectin ratio, 
systemic low -grade inflammation, and anisocy-
tosis in optimally treated patients with T2D and 
established ASCVD.
METHODS Subjects The stu dy included 126 
consecutive outpatients who had T2D and an-
giographically documented CAD, peripheral 
artery disease, or extracranial artery disease. 
The exclusion criteria were as follows: type 1 
diabetes, poorly controlled T2D with hemoglo-
bin A1c (HbA1c) levels higher than 9%, a histo-
ry of coronary intervention or coronary artery 
bypass grafting (≤1 month), a history of acute 
coronary syndrome (≤3 months), moderate -to-
-severe anemia (hemoglobin levels <10 g/dl), 
treatment with iron, acute infection, hypertri-
glyceridemia, liver injury, chronic therapy with 
nonsteroidal anti -inflammatory drugs (except 
for acetylsalicylic acid), pregnancy, alcohol or 
drug abuse, life expectancy less than 12 months 
due to any concomitant diseases, and abnor-
mal results of laboratory tests or imaging that 
would hamper the interpretation of findings. 
Finally, 68 patients with well -controlled T2D 
WHAT’S NEW?
There is accumulating evidence that red blood cell distribution width (RDW), 
reflecting the degree of anisocytosis in vivo, is an independent predictor of poor 
prognosis in type 2 diabetes (T2D) and atherosclerotic cardiovascular disease 
(ASCVD). To the best of our knowledge, this is the first study to show that 
in patients with well -controlled T2D and established ASCVD, the RDW values 
are associated with leptin-to-adiponectin imbalance. Furthermore, a significant 
relationship was found between RDW and selected inflammatory markers. 
We believe that these findings will help understand the mechanisms underlying 
increased anisocytosis in patients with T2D and ASCVD as well as improve 
knowledge of its association with worse prognosis in this patient population.
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considered significant. All calculations were per-
formed using the Statistica 13.3 software package 
(StatSoft, Inc., Tulsa, Oklahoma, United States).
RESULTS Baseline characteristics Final-
ly, 68 patients aged 47 to 85 years (mean [SD], 
65.3 [6.8] years) and including 21 women (30.9%) 
were enrolled. The baseline characteristics of 
the study patients are shown in TABLE 1. There 
were no intergroup differences in baseline de-
mographics. Regarding clinical characteristics, 
only a history of percutaneous coronary inter-
ventions was more frequent in the group with 
RDW ≥13.5% compared with the group with 
RDW <13.5% (77.1 vs 51.5%; P = 0.03) (TABLE 1).
Patients with RDW ≥13.5% had significant-
ly lower mean (SD) levels of hemoglobin (13.2 
[1.3] g/dl vs 13.9 [1.3] g/dl; P = 0.02), MCH (28.9 
[1.8] pg vs 29.8 [1.3] pg; P = 0.01), and MCHC 
(33.2 [0.9] g/dl vs 34.1 [0.8] g/dl; P <0.001) com-
pared with those with RDW  <13.5% (TABLE 2). 
Anemia was diagnosed in 17.6% of the study 
patients. There were no differences in its prev-
alence between the studied groups (12.1% vs 
22.9%; P = 0.25). In addition, subjects with high-
er RDW had decreased HDL -C levels (1.05 [0.8–
1.35] mmol/l vs 1.26 [1.11–1.54] mmol/l; P = 0.03). 
The groups did not differ in HbA1c levels (TABLE 2).
1-myristoyl-2-(4-nitrophenylsuccinylphospha-
tidylcholine) was used as a substrate.
The atherogenic index of plasma was calculat-
ed as log(TG/HDL -C), with TG and HDL -C ex-
pressed in molar concentrations, as described 
elsewhere.22
Statistical analysis Data were expressed as 
numbers and percentages for categorical vari-
ables and as mean (SD) or median (interquar-
tile range) for the continuous variables, depend-
ing on their distribution. The Shapiro–Wilk 
test was used to determine normal distribution 
among continuous variables. Differences be-
tween the groups were assessed using the t test 
for normally distributed continuous variables 
or by the Mann–Whitney test for nonnormal-
ly distributed variables. The Pearson χ2 test or 
the Fisher exact test (when any expected cell fre-
quency was less than 5) were used to evaluate 
the differences in categorical variables between 
the respective study groups. Correlations were 
calculated with the Pearson coefficient. Stepwise 
linear regression analysis was performed to de-
termine the independent predictors of RDW in 
the study patients. The final multivariable model 
included variables that were significant univari-
ate predictors and did not exhibit significant col-
linearity. Two -sided P values less than 0.05 were 
TABLE 1 Baseline characteristics of the study population
Variable Whole group (n = 68) RDW <13.5% (n = 33) RDW ≥13.5% (n = 35) P value
Age, y, mean (SD) 65.3 (6.8) 64.7 (7.2) 65.9 (6.4) 0.46
Female sex, n (%) 21 (30.9) 9 (27.3) 12 (34.3) 0.53
Hypertension, n (%) 66 (97.1) 31 (93.9) 35 (100) 0.23
Hyperlipidemia, n (%) 47 (69.1) 23 (69.7) 24 (68.6) 0.92
Metabolic syndrome, n (%) 68 (100) 33 (100) 35 (100) >0.99
Obesity, n (%) 44 (64.7) 22 (66.7) 22 (62.9) 0.74
Waist circumference, cm, mean (SD) 106.5 (9.8) 104.7 (8.7) 108 (10.6) 0.19
BMI, kg/m2, mean (SD) 31.1 (3.6) 31 (3.5) 31.2 (3.9) 0.85
Body fat, %, mean (SD) 33.8 (8.4) 34.4 (7.9) 33.3 (9) 0.61
Visceral fat, %, mean (SD) 16.1 (4.8) 16.4 (4.2) 15.5 (5.7) 0.52
Total body water, %, median (IQR) 47.5 (44.3–49.3) 47.6 (44.3–49) 46.3 (43.7–49.8) 0.9
Muscle mass, kg, mean (SD) 54.9 (10.5) 55.1 (9.8) 54.8 (10.5) 0.93
Medical history
T2D duration, y, median (IQR) 10 (6–15) 9.5 (4–13) 10 (6–15) 0.71
CAD, n (%) 68 (100) 33 (100) 35 (100) >0.99
PAD, n (%) 23 (33.8) 10 (30.3) 13 (37.1) 0.55
Previous MI, n (%) 27 (39.7) 11 (33.3) 16 (45.7) 0.3
Previous PCI, n (%) 44 (64.7) 17 (51.5) 27 (77.1) 0.03
Abbreviations: BMI, body mass index; CAD, coronary artery disease; IQR, interquartile range; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous 
coronary intervention; RDW, red blood cell distribution width; T2D, type 2 diabetes
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TABLE 2 Hematological and glycometabolic parameters in the study patients
Variable Whole group (n = 68) RDW <13.5% (n = 33) RDW ≥13.5% (n = 35) P value
RBC, × 106/µl 4.6 (0.4) 4.7 (0.4) 4.6 (0.4) 0.4
Hemoglobin, g/dl 13.6 (1.3) 13.9 (1.3) 13.2 (1.3) 0.02
Hematocrit, % 40.4 (3.7) 40.9 (3.6) 39.8 (3.8) 0.23
MCV, fl 87.2 (3.8) 87.6 (3.1) 86.9 (4.4) 0.49
MCH, pg 29.3 (1.6) 29.8 (1.3) 28.9 (1.8) 0.01
MCHC, g/dl 33.6 (1) 34.1 (0.8) 33.2 (0.9) <0.001
WBC, × 103/µl, median (IQR) 7.4 (6.4–9.1) 7.2 (6.4–7.9) 7.4 (6.4–9.8) 0.17
Neutrophils, × 103/µl, median (IQR) 4.4 (3.4–5.6) 4.4 (3.4–5.2) 4.7 (3.3–6.3) 0.39
Lymphocytes, × 103/µl, median (IQR) 2.1 (1.7–2.6) 2.1 (1.7–2.5) 2.2 (1.8–2.7) 0.15
Platelets, × 103/µl, median (IQR) 221 (174.5–277) 220 (203–252) 222 (154–310) >0.99
MPV, fl 10.5 (1.3) 10.7 (1) 10.4 (1.5) 0.28
TC, mmol/l 3.85 (0.9) 4 (0.95) 3.71 (0.83) 0.19
LDL -C, mmol/l, median (IQR) 1.91 (1.53–2.69) 2.2 (1.63–2.85) 1.79 (1.45–2.47) 0.14
HDL -C, mmol/l, median (IQR) 1.22 (0.93–1.44) 1.26 (1.11–1.54) 1.05 (0.8–1.35) 0.03
TG, mmol/l, median (IQR) 1.4 (0.99–1.93) 1.32 (1.05–1.75) 1.47 (0.96–2.09) 0.44
AIP 0.1 (0.3) 0.04 (0.25) 0.15 (0.34) 0.14
HbA1c, %, median (IQR) 7 (6.6–7.45) 6.9 (6.6–7.5) 7 (6.6–7.3) 0.93
Insulin, mU/ml, median (IQR) 20.6 (13.1–33) 18.87 (12.5–28.6) 22.1 (16.3–33.2) 0.49
C -peptide, ng/ml 3.3 (1.43) 2.99 (1.29) 3.6 (1.52) 0.08
Creatinine, µmol/l 84.4 (19.1) 84.3 (18.1) 84.5 (20.1) 0.97
eGFR, ml/min/1.73 m2, median (IQR) 78.3 (68.5–90) 78.0 (72.5–88) 85.00 (67–90) 0.49
Data are given as mean (SD) unless otherwise indicated.
Abbreviations: AIP, atherogenic index of plasma; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL -C, high -density lipoprotein cholesterol; 
LDL -C, low -density lipoprotein cholesterol; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; 
MPV, mean platelet volume; RBC, red blood cell; TC, total cholesterol; TG, triglycerides; WBC, white blood cell; others, see TABLE 1
TABLE 3  Adipokines and inflammatory markers in the study patients
Variable Whole group (n = 68) RDW <13.5% (n = 33) RDW ≥13.5% (n = 35) P value
Leptin, ng/ml 3.57 (1.71–7.65) 3.19 (1.16–7.15) 3.7 (2.25–9) 0.15
Adiponectin, µg/ml 3.73 (2.74–4.88) 4 (3.13–5.69) 3.44 (2.64–4.15) 0.13
Leptin-to-adiponectin ratio, ng/µg 0.93 (0.36–2.09) 0.66 (0.31–1.25) 1.7 (0.49–2.31) 0.04
hs -CRP, mg/l 1.52 (0.72–2.68) 1.66 (0.72–2.59) 1.43 (0.82–2.73) 0.97
IL-6, pg/ml 1.95 (1.56–2.76) 1.88 (1.46–2.34) 2.14 (1.62–3.19) 0.19
TNF -α, pg/ml 1.48 (1.27–1.77) 1.39 (1.18–1.57) 1.58 (1.42–1.97) 0.02
Myeloperoxidase, ng/ml 31.57 (19.22–48.2) 33.12 (22.76–52.88) 31.11 (14–47.22) 0.31
sICAM-1, ng/ml 211.90 (169.12–250.08) 198.96 (152.75–231) 224.83 (183.18–290.65) 0.07
sVCAM-1, ng/ml 983.06 (716.97–1504.74) 1138.24 (684.56–1545.27) 944.79 (730.76–1373.93) 0.54
Lp -PLA2, ng/ml, mean (SD) 138.53 (62.41) 136.88 (72.3) 140.1 (52.44) 0.83
Data are given as median (IQR) unless otherwise indicated.
Abbreviations: hs -CRP, high -sensitivity C -reactive protein; IL-6, interleukin 6; Lp -PLA2, lipoprotein -associated phospholipase A2; sICAM-1, soluble intercellular adhesion 
molecule 1; sVCAM‑1, soluble vascular cell adhesion molecule 1; TNF ‑α, tumor necrosis factor alpha; others, see TABLE 1
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FIGURE 1  Distribution of adipokines and inflammatory markers in patients with lower (<13.5%) and higher (≥13.5%) red blood cell distribution width (RDW): 
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sICAM-1 levels (β = 0.21; 95% CI, 0.02–0.41; 
P = 0.03), and MCHC (β = –0.48; 95% CI, –0.67 
to –0.28; P <0.001) were independent predictors 
of RDW in our patients.
DISCUSSION To our knowledge, this is the first 
study to show that anisocytosis is associated 
with leptin-to-adiponectin imbalance in patients 
with very high cardiovascular risk, T2D, and es-
tablished ASCVD. Furthermore, a relationship 
was found between RDW and selected inflam-
matory markers.
RDW is a simple, inexpensive, and common-
ly available hematological parameter, which re-
flects the degree of anisocytosis in vivo.23 In ev-
eryday clinical practice, RDW is most often used 
for the differential diagnosis of anemias.10,14,24‑26 
Importantly, there is emerging evidence sug-
gesting a link between increased RDW and poor 
outcomes in the general population,27,28 in pa-
tients with CAD,29‑31 and those with T2D and 
heart failure.14 Additionally, a significant rela-
tionship was found between RDW and the prev-
alence of T2D,12,13 metabolic syndrome,32 and 
heart failure.33 These associations were inde-
pendent of other hematological parameters in-
cluding MCV, hemoglobin concentration, and 
hematocrit levels.14 Furthermore, in patients 
with chronic coronary syndromes, increased 
RDW was related to greater comorbidity bur-
dens (ie, T2D, chronic kidney disease, atrial fi-
brillation, peripheral artery disease, and heart 
failure).7 Of note, increased RDW was associat-
ed with impaired microvascular perfusion and 
Leptin-to-adiponectin ratio and inflamma-
tory markers Our study showed that pa-
tients with RDW  ≥13.5% had significantly 
higher serum leptin-to-adiponectin ratio (1.7 
[0.49–2.31] ng/µg vs 0.66 [0.31–1.25] ng/µg; 
P = 0.04) and TNF -α levels (1.58 [1.42–1.97] 
pg/ml vs 1.39 [1.18–1.57] pg/ml; P = 0.02) (TABLE 3 
and FIGURE 1). There were no significant differenc-
es in the concentrations of other inflammato-
ry markers (TABLE 3).
Correlations We found that leptin-to-adi-
ponectin ratio (r = 0.25; P = 0.04) and the lev-
els of TNF -α (r = 0.32; P = 0.01) and sICAM-1 
(r = 0.31; P = 0.01) were positively correlated 
with RDW. No significant associations were ob-
served between RDW and the levels of leptin and 
adiponectin. Furthermore, other inflammatory 
markers, such as hs -CRP and IL-6, were also not 
significantly related to the RDW. On the other 
hand, the significant correlations were found be-
tween circulating leptin and IL-6 levels (r = 0.28; 
P = 0.02) and between the leptin-to-adiponectin 
ratio and IL-6 levels (r = 0.31; P = 0.01).
Linear regression analysis The  signifi-
cant predictors of RDW are presented in TABLE 4. 
After adjusting for age and sex, WBC, neu-
trophils, lymphocytes, serum TNF -α levels, 
sICAM-1 levels, and the leptin-to-adiponectin 
ratio remained significantly associated with 
RDW (TABLE 4). A multivariable linear regression 
analysis, which included demographic, clinical, 
and laboratory parameters, showed that WBC 
count (β = 0.25; 95% CI, 0.05–0.45; P = 0.01), 
TABLE 4 Linear regression analysis of red blood cell distribution width in the study patients
Variable Unadjusted model Adjusted modela
β (95% CI) P value β (95% CI) P value
WBC, × 103/µl 0.43 (0.21–0.66) <0.001 0.44 (0.22–0.67) <0.001
Neutrophils, × 103/µl 0.35 (0.11–0.58) 0.005 0.35 (0.11–0.59) 0.005
Platelets, × 103/µl 0.33 (0.1–0.56) 0.006 0.35 (0.12–0.59) 0.004
TNF -α, pg/ml 0.3 (0.06–0.53) 0.013 0.30 (0.06–0.54) 0.015
sICAM-1, ng/ml 0.3 (0.07–0.54) 0.012 0.33 (0.09–0.57) 0.008
History of PCI 0.26 (0.03–0.5) 0.029 0.26 (0.03–0.51) 0.033
Leptin-to-adiponectin ratio, ng/µg 0.25 (0.01–0.48) 0.044 0.24 (0.01–0.49) 0.048
Lymphocytes, × 103/µl 0.23 (–0.01 to 0.48) 0.062 0.26 (0.01–0.52) 0.043
MCV, fl –0.22 (–0.46 to 0.02) 0.077 –0.25 (–0.5 to 0.01) 0.056
Hemoglobin, g/dl –0.23 (–0.47 to 0.01) 0.055 –0.33 (–0.61 to –0.05) 0.02
MPV, fl –0.36 (–0.59 to –0.13) 0.003 –0.36 (–0.59 to –0.13) 0.003
MCH, pg –0.46 (–0.68 to –0.24) <0.001 –0.47 (–0.69 to –0.25) <0.001
MCHC, g/dl –0.57 (–0.77 to –0.36) <0.001 –0.61 (–0.83 to –0.4) <0.001
a Adjusted for age and sex
Abbreviations: see TABLES 1‑3
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antiatherogenic properties.37 An increasing body 
of evidence suggests that hypoadiponectinemia 
is involved in the pathogenesis of T2D, CAD, and 
hypertension.37 Adiponectin has been shown to 
enhance the proliferation of hematopoietic stem 
cells and maintain their undifferentiated state.36
The results of our study showed that the 
leptin-to-adiponectin ratio was significantly 
related to the RDW values. This relationship was 
relevant after adjusting for age and sex. However, 
after considering all demographic, clinical, and 
laboratory data, the leptin-to-adiponectin ratio 
did not turn out to be an independent predic-
tor of RDW in multivariable analysis. We pos-
tulate that this may reflect the significant yet 
not key role of this imbalance of adipokines in 
erythropoiesis in patients with well -controlled 
T2D and ASCVD.
As the leptin-to-adiponectin ratio is a well-
-established marker of adipose tissue dys-
function, strongly associated with the  sur-
rogate measures of insulin resistance such as 
the homeostatic model assessment (HOMA), 
the hyperinsulinemic -euglycemic clamp, and 
the quantitative insulin sensitivity check index 
(QUICKI) in various cohorts,38,39 we hypothe-
size that RDW values can reflect the severity of 
adiposopathy and insulin resistance in diabet-
ic patients with very high cardiovascular risk 
and documented ASCVD. Interestingly, Inoue 
et al40 showed that the leptin-to-adiponectin ra-
tio in individuals with T2D was correlated with 
insulin resistance even stronger than HOMA. 
It has also been suggested that an  elevated 
leptin-to-adiponectin ratio may be a useful ath-
erosclerotic index in patients with T2D.41 In ad-
dition, leptin-to-adiponectin imbalance was as-
sociated with increased vasoconstriction caused 
by angiotensin II.37
Leptin-to-adiponectin ratio and chronic in-
flammation Chronic systemic inflammation 
plays a crucial role in the pathogenesis of T2D 
and its macrovascular complications.1‑5 It is well 
known that low -grade inflammation is closely 
linked to all stages of ASCVD.42,43
Leptin and adiponectin have opposing effects on 
systemic inflammation.37 Leptin upregulates pro-
inflammatory cytokines including IL-6 and TNF-
-α, which are associated with insulin resistance 
and T2D.37 In contrast, adiponectin downregu-
lates the expression of various proinflammatory 
mediators and exerts anti -inflammatory proper-
ties.37 Our study is consistent with these observa-
tions, as we found a significant positive correlation 
between leptin and IL-6 levels as well as between 
the leptin-to-adiponectin ratio and IL-6 levels.
Anisocytosis and systemic inflammation 
Chronic inflammation may influence erythro-
poiesis, including RBC circulatory half -life and 
RBC deformability, and therefore increase RDW 
could cause tissue hypoxia in patients with CAD, 
even in those without anemia.7
It is well documented that RDW increas-
es under conditions of enhanced or ineffective 
RBC production (erythropoiesis) as well as en-
hanced RBC destruction.14,34 The pathophysio-
logical mechanisms underlying increased RDW 
in patients with T2D and ASCVD are complex 
and not fully understood. A number of poten-
tial mechanisms have been proposed including 
harmful effects of hyperglycemia on RBCs (ie, 
rearrangement of RBC membranes, changes in 
the mechanical properties of cell membranes and 
cell metabolism, disturbance of oxygen binding 
to hemoglobin), bone marrow depression, chronic 
inflammation and related dysregulation of iron 
homeostasis, oxidative stress, and nutritional de-
ficiencies (eg, of vitamin B12, folic acid, or iron).
14
Adipokine imbalance and anisocytosis 
During erythropoiesis, numerous transcrip-
tion factors, chromatin modifiers, cytokines, 
and hormones stimulate the  proliferation 
and maturation of erythroid progenitors.22,35 
In the  present study, we found that serum 
leptin-to-adiponectin ratio was associated with 
RDW, a quantitative measure of anisocytosis. 
There is growing evidence that adipose tissue 
produces and actively secretes a plethora of bi-
ologically active adipokines that may disturb 
erythropoiesis by interacting with various met-
abolic and inflammatory pathways.16,20 In this 
context, it is very interesting that adipocytes ac-
count for about 50% of bone marrow cells and 
occupy 70% of adult bone marrow volume.15,36
Leptin is a 16-kDa peptide hormone, produced 
predominantly by mature adipocytes, which is 
involved in regulating body energy balance and 
body fat.16 In adults, serum leptin levels are cor-
related with the percentage of body fat.16 Al-
though the main role of leptin is to regulate body 
weight through its anorectic effect on the hypo-
thalamus, this adipokine also has other func-
tions, including stimulation of hematopoie-
sis and modulation of immune homeostasis.16 
The leptin receptor (LEP -R) has been shown to 
be present at the cell membranes of hemato-
poietic cells including hematopoietic progeni-
tor cells and erythropoietic, lymphoblastic, and 
myeloid cell lines.16,18 Studies on in vitro and an-
imal models confirmed the key role of leptin 
at the early stages of erythropoiesis.35 In addi-
tion to significant direct proliferative effects on 
erythroid precursor cells, leptin may also stim-
ulate the differentiation of cells of erythrocytic 
lineage.16 Furthermore, it has been demonstrat-
ed that leptin acts synergistically with erythro-
poietin to promote erythropoiesis.15,16
In turn, adiponectin is an adipocyte -derived 
hormone whose serum levels are negatively reg-
ulated by accumulation of visceral fat.37 Adipo-
nectin has anti -inflammatory, antidiabetic, and 
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small and a larger sample would probably pro-
vide more robust findings. Finally, investigating 
iron metabolism and hypoferremia could help 
clarify the association between RDW, system-
ic inflammation, and the leptin-to-adiponectin 
ratio in patients with T2D and ASCVD.
Conclusions Our study showed that RDW val-
ues in patients with well -controlled T2D and AS-
CVD were associated with leptin-to-adiponectin 
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values.44 A shortened RBC half -life was reported 
for T2D and metabolic syndrome and associat-
ed with increased anisocytosis.32,45 These mech-
anisms may explain the relationship between in-
creased RDW and chronic subclinical inflamma-
tion, which is typical of diabetes. Recent studies 
have also shown that systemic inflammation may 
increase the degree of anisocytosis by inducing 
the expression of hepcidin, which inhibits in-
testinal iron absorption and iron release from 
macrophages.46 Furthermore, it has been shown 
that proinflammatory cytokines can directly af-
fect erythropoiesis by inhibiting the prolifera-
tion of erythroid progenitor cells and impair-
ing the erythropoietin gene expression, which 
leads to increased RDW.46,47 It was found that 
TNF -α inhibits the growth of burst- and colony-
-forming unit–erythroid cells.46 Previous stud-
ies have also shown that proinflammatory cyto-
kines inhibit erythropoietin -induced RBC matu-
ration.46 Therefore, some researchers, yet not all, 
suggest that RDW may be a simple marker of sys-
temic low -grade inflammation in various clini-
cal entities including T2D.12‑14,32,44,47 In line with 
these observations, we found a positive correla-
tion of RDW with serum TNF -α and sICAM-1 (a 
marker of vascular inflammation) levels. Fur-
thermore, univariate and multivariable linear 
regression analyses showed a significant asso-
ciation between selected inflammatory mark-
ers and RDW. Interestingly, we did not find any 
relationship between RDW and hs -CRP. There 
is strong evidence that both TNF -α and IL-6 in-
duce the expression of hs -CRP in the liver and are 
more sensitive inflammatory markers than hs-
-CRP.48 In addition, this may be due to the mod-
ulating effect of obesity on the relationship be-
tween chronic inflammation and anisocytosis 
in the study patients. Of note, obesity occurred 
in 64.7% of our patients and the mean (SD) body 
mass index was 31.1 (3.6) kg/m2. Vayá et al47 did 
not find a relationship between inflammatory 
markers and RDW in the morbidly obese patients, 
which may partly explain our results.
Chung et al17 demonstrated that leptin can di-
rectly regulate hepatic expression of hepcidin. It 
has been shown that increased hepcidin biosyn-
thesis in the presence of leptin decreases duode-
nal iron absorption and impairs iron metabolism, 
which can lead to hypoferremia.17 In the present 
study, we did not evaluate iron metabolism in our 
patients; however, the strong and independent 
inverse relationship between RDW and MCHC 
suggests that the pathomechanism proposed by 
Chung et al,17 rather than the direct impact of sys-
temic inflammation, plays a key role in the mech-
anisms of anisocytosis in our study patients.
Study limitations This study had several lim-
itations. First, our study, although prospective 
and dual -center, focused on a selected group of 
patients. Second, the sample size was relatively 
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